Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide
Research output: Contribution to journal › Review › Research › peer-review
Insulin therapy in the management of Type 2 diabetes is often postponed and/or not adequately intensified to maintain glycemic control because of the risk of weight gain and hypoglycemia. A fixed combination of the long-acting insulin degludec and liraglutide has recently been accepted by the EMA for the management of Type 2 diabetes. The incentive for this combination is to exploit the advantages of each of the drugs while counterbalancing the side effects. Insulin degludec effectively reduces fasting plasma glucose, but carries the risk of hypoglycemia and body weight gain. Liraglutide, on the other hand, exerts glycemic control with a minimal risk of hypoglycemia and, at the same time, reduces appetite and body weight.
Original language | English |
---|---|
Journal | Expert Review of Clinical Pharmacology |
Volume | 8 |
Issue number | 3 |
Pages (from-to) | 273-282 |
Number of pages | 10 |
ISSN | 1751-2433 |
DOIs | |
Publication status | Published - 1 May 2015 |
Bibliographical note
Publisher Copyright:
© Informa UK, Ltd.
- Basal insulin, DUAL I, DUAL II, fixed combination, GLP-1RA, IDegLira, incretin mimetic, insulin degludec, liraglutide, Type 2 diabetes
Research areas
ID: 305736595